[Special Stock] KainosMed Rises on Parkinson's Disease Treatment Patent Acquisition
[Asia Economy Reporter Hwang Yoon-joo] Kainosmed recorded a limit-up following news of obtaining a patent related to a Parkinson's disease treatment.
As of 9:20 AM on the 2nd, Kainosmed is trading at 2,475 KRW, up 29.92% from the previous trading day, hitting the upper price limit.
On the same day, Kainosmed announced the successful development of a salt form that increases the solubility of 'KM-819' and the acquisition of a patent for it in the United States.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
KM-819 is a candidate drug developed by Kainosmed as a treatment for Parkinson's disease and multiple system atrophy, having received Phase 2 clinical trial approval in Korea and the United States. This patent covers a substance that increases the solubility of KM-819 by more than 2,000 times, which enhances absorption in the human body after administration, allowing for a significantly reduced dosage.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
